We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
Eli Lilly acquires Maze Therapeutics with obesity drug for $2.1 billion. Breakdown of terms, hidden risks, and benefits for investors. Read more.
